Apollo Tyres / Q3-FY26

Read the quarter in context.

A source-linked quarter view: reported numbers, management language, guidance, and the risks that should carry forward.

Research layer active

ConCallIQ research layer

Signal, with the source still visible.

Use the controls below to narrow the view, then follow the evidence into the next layer of context.

Positive2026-02-10Back to APOLLOTYRE

Revenue

₹7,740 Cr

verified against source

Revenue YoY

12%

reported change

EBITDA

₹1,190 Cr

latest reported figure

Source

screener in

record provenance

Actual signal trajectory

Where this quarter sits.

source records only
EBITDA (₹ Cr)PositiveWatchNegative
5 actual records
Actual quarterly EBITDA (₹ Cr) trajectoryReported values plotted by quarter. Hover or focus a point for its quarter, value, and source sentiment.Q2 FY25: 880 · Watch source sentiment · 2024-11-12Q2 FY25Q3 FY25: 950 · Watch source sentiment · 2025-02-07Q3 FY25Q2 FY26: 1,020 · Positive source sentiment · 2025-11-15Q2 FY26Q3 FY26: 1,190 · Positive source sentiment · 2026-02-10Q3 FY26Q4 FY26: 1,070 · Watch source sentiment · 2026-05-15Q4 FY261,190880
Values are taken from the available verified source records; sentiment color is a separate source-read indicator.

Quarter read

What the record says.

Apollo Tyres reported a strong Q3 FY26 with consolidated revenue of ₹7,740 crore (+12% YoY) and EBITDA margin of 15.3% (+160 bps YoY), driven by robust domestic demand across all channels and categories. India revenue grew 13%+ to ₹5,140 crore, with mid-teens volume growth and exports up nearly 20%. Europe remained flattish due to muted demand. The company announced a ₹5,800 crore CapEx plan for Andhra Pradesh over FY27-29 to address capacity constraints (India utilization in high 80s). A&P spend spiked to ~₹150 crore due to BCCI sponsorship activation, but is expected to normalize to 2.5% of sales. Raw material costs are expected to remain steady in Q4. Risk: Europe demand recovery remains uncertain and could delay margin improvement.

Colored figures show movement against the previous available record.

Guidance to track

  • Board approved ₹5,800 crore CapEx for expanding PCR and TBR capacities in Andhra Pradesh, spread over FY27-29, with growth CapEx of ~₹2,000 crore in FY27.
  • Overall consolidated CapEx for FY27 is expected to be around ₹3,000 crore, including Hungary expansion and maintenance.
  • A&P spend as a percentage of sales will increase to about 2.5% in a normalized scenario, up from ~2% historically, to drive top-line growth.
  • The Netherlands plant will stop production by end of June 2026, with benefits expected to flow from H2 FY27.

Risks flagged

  • Europe market growth was -4% in Q3, and recovery is uncertain; continued weakness could delay margin improvement.
  • Global events cause unpredictable swings in raw material prices; management expects flattish costs but cannot rule out adverse moves.
  • The large CapEx cycle could temporarily depress ROCE, which is currently 13.5%, below the 15% target.
  • Elevated A&P spend due to BCCI sponsorship may take time to normalize, impacting near-term margins.

Key quotes

  • We closed Q3 with consolidated top-line growth of nearly 12% and an EBITDA margin of 15.3%.
  • Our current capacity utilization level in India is in the high 80s, and given our growth expectations for the near future, we would start hitting capacity limitations soon.
  • We would probably need to take a mid-single-digit kind of price increase every year.

Research modules

Go one layer deeper.